Inflammation Mediated Epileptogenesis as Possible Mechanism Underlying Ischemic Post-stroke Epilepsy

Anna Regina Tröscher1, Joachim Gruber1,2, Judith N. Wagner1,2, Vincent Böhm1,2, Anna-Sophia Wahl3,4 and Tim J. von Oertzen1,2*

1Neurology I, Neuromed Campus, Kepler Universitätsklinikum, Linz, Austria, 2Medical Faculty, Johannes Kepler University, Linz, Austria, 3Brain Research Institute, University of Zurich, Zurich, Switzerland, 4Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany

Post-stroke Epilepsy (PSE) is one of the most common forms of acquired epilepsy, especially in the elderly population. As people get increasingly older, the number of stroke patients is expected to rise and concomitantly the number of people with PSE. Although many patients are affected by post-ischemic epileptogenesis, not much is known about the underlying pathomechanisms resulting in the development of chronic seizures. A common hypothesis is that persistent neuroinflammation and glial scar formation cause aberrant neuronal firing. Here, we summarize the clinical features of PSE and describe in detail the inflammatory changes after an ischemic stroke as well as the chronic changes reported in epilepsy. Moreover, we discuss alterations and disturbances in blood-brain-barrier leakage, astrogliosis, and extracellular matrix changes in both, stroke and epilepsy. In the end, we provide an overview of commonalities of inflammatory reactions and cellular processes in the post-ischemic environment and epileptic brain and discuss how these research questions should be addressed in the future.

Keywords: neuroinflammation, ischemia, post-stroke seizures, gliosis, BBB leakage

INTRODUCTION

Ischemic strokes are among the most common causes of death and account for a large proportion of disabilities in Western societies (Deuschl et al., 2020). Importantly, cerebrovascular diseases are one of the main reasons for acquired epilepsy in adulthood, so-called post-stroke epilepsy (PSE; Pitkänen et al., 2016). With the rising number of geriatric patients worldwide, the number of stroke patients, and hence PSE patients, can be expected to rise significantly in the next decades (Deuschl et al., 2020). Although good descriptions and reviews of current clinical knowledge of PSE are available (Pitkänen et al., 2016; Feyissa et al., 2019; Xu, 2019; Zelano et al., 2020; Galovic et al., 2021), surprisingly little is known about the underlying pathomechanism that leads to PSE. Therefore, treatment and preventive actions are limited and speculative.

Common hypotheses for the post-ischemic epileptogenesis include gliosis, chronic inflammation, angiogenesis, neurodegeneration, altered synaptic plasticity, or synaptic sprouting (Li et al., 2010; Feyissa et al., 2019). Additionally, blood-brain-barrier (BBB) leakage during...
stroke induces inflammation and pro-epileptogenic mechanisms (Vezzani et al., 2019). Mitochondrial dysfunction, edema, or ion gradient imbalances might contribute to stroke lesion size as well as to seizure generation. Moreover, seizure-like brain activity during ischemia also increases the infarct size and negatively impacts functional recovery (Williams and Tortella, 2002). This suggests that post-ischemic pathological changes and seizure generation are reciprocal processes which influence each other (Feyissa et al., 2019).

We here summarize clinical features of PSE and describe characteristics of neuroinflammation, blood-brain-barrier perturbations, gliosis, and changes in the extracellular matrix in stroke and epilepsy. Furthermore, we delineate similarities and possible interactions between the two pathologies and propose future directions for investigating the underlying pathomechanism in PSE in a preclinical and translational approach.

**POST-STROKE EPILEPSY**

Post-stroke seizures occur frequently and can be categorized into acute symptomatic (≤7 days post-stroke, ASS) and remote symptomatic seizures (>7 days post-stroke, RSS). ASS is considered to be the result of local metabolic imbalances (Feyissa et al., 2019). Although ASS drastically increases the risk for developing RSS, they do not contribute to the diagnosis of PSE. However, all patients who develop a single seizure more than 7 days after a stroke are classified as suffering from PSE as they have a 71.5% increased risk of developing further seizures within the next 10 years (Hesdorffer et al., 2009) and hence fall into the category of epilepsy according to the International League against Epilepsy (Fisher et al., 2014). Numbers of patients developing PSE vary due to different cohorts regarding the length of follow-up, stroke etiology, or varying definitions of early and RSS, but generally range from 3 to 25% (Galovic et al., 2018, 2021; Feyissa et al., 2019; Xu, 2019; Ferreira-Atuesta et al., 2021). Risk factors for PSE include strokes with cortical involvement, stroke severity, young age (below 65 years), or ASS (Galovic et al., 2018; Feyissa et al., 2019; Zelano et al., 2020; Ferreira-Atuesta et al., 2021).

Hemorrhagic strokes, which only make up about 5–10% of strokes, are more epileptogenic than ischemic ones (Caplan and Kase, 2016). ASS appears in between 2% and 4% of patients with ischemic strokes vs. 10% to 16% of patients with intracranial hemorrhages (Haapaniemi et al., 2014; Wang et al., 2017; Thevathasan et al., 2018). These numbers may be an underestimate, as a study postulates that up to a fifth of patients showed electroencephalographic seizures in the acute phase after stroke (Bentes et al., 2017). The incidence of late-onset post-stroke seizures at a 5-year follow-up has been reported to be 9.5% for ischemic strokes and 11.8% for hemorrhagic strokes (Haapaniemi et al., 2014; Holtkamp et al., 2017).

Approximately 70% of PSE patients develop focal seizures, which occasionally generalize. The remaining 30% have bilateral tonic-clonic seizures only (Xu, 2019). PSE does not only lead to decreased quality of life, as does epilepsy in general, but it has also been linked with decreased post-stroke recovery, neurological deterioration, and poor functional outcomes (Graham et al., 2013; Baranowski, 2018; Feyissa et al., 2019). Seizures in PSE patients are often well manageable with anti-epileptic therapy (AED, anti-epileptic drugs), however, up to 40% of patients remain unresponsive to pharmacological intervention (Feyissa et al., 2019; Xu, 2019). General prophylactic AED treatment after stroke is not advisable, as this has been reported to decrease behavioral and motor recovery by inhibiting neural plasticity (Messé et al., 2009). Moreover, long-term AED usage may increase the risk of atherosclerosis, which would pose an additional risk for post-stroke patients (Tan et al., 2009).

Although there are some clinical tools available to determine the risk of developing PSE after ischemic, hemorrhagic, or both stroke types (Strzelczyk et al., 2010; Haapaniemi et al., 2014; Galovic et al., 2018; Lekoubou et al., 2021), an easily measurable biomarker would ameliorate early diagnosis and facilitate preventive treatment even before the first seizure has occurred. In search of imaging biomarkers predicting the risk of poststroke seizures, a significant association between the incidence of PSE 2 years after the occurrence of hemorrhagic transformation post ischemic stroke in patients who underwent endovascular revascularization therapy was found (17.9% compared with 4.0%, \( p = 0.001; \) Thevathasan et al., 2018). In a recent study no impact of reperfusion techniques on the development of PSE was found (Ferreira-Atuesta et al., 2021).

Although RSS is significantly associated with stroke severity and stroke location in the middle cerebral artery territory among others (Galovic et al., 2018), no explicit information regarding more accurate stroke localization, infarct size, or concomitant cerebrovascular damages, for example microangiopathy, or loss in brain volume, is available.

Unfortunately, hardly anything is known about the pathomechanism of post-ischemic epileptogenesis on a cellular and molecular level. A better understanding of these processes would help to search for possible biomarker candidates in easily accessible compartments such as the blood and could identify patients at risk of developing PSE in a paraclinical setting.

**Neuroinflammation as Possible Mechanism Underlying PSE**

An ischemic insult induces a plethora of processes in the brain parenchyma, such as excitotoxicity, hypoxic injury, activation of the immune system, and BBB leakage (Wimmer et al., 2018; Jayaratj et al., 2019). Interestingly, similar mechanisms have been described to induce epileptogenesis (Figure 1; Bauer et al., 2017; Vezzani et al., 2019). Especially neuroinflammation-mediated epilepsy has become a focus of attention in recent years. Several immunological mediators have been shown to lower the seizure threshold. Innate as well as adaptive neuroinflammation has repeatedly been shown in the brain parenchyma in several forms of epilepsy (Vezzani et al., 2011a; Devinsky et al., 2013; Bauer et al., 2017).

**Neuroinflammation in Stroke**

Post-ischemic inflammation occurs rapidly after the event and is characterized by microglia activation, influx of peripheral immune cells, and BBB breakdown.
Inflammation and Post-stroke Epileptogenesis

In the early stage after a stroke, acute neuronal and glial cell death occurs within the necrotic area. Peripheral immune cells, above all macrophages, neutrophils, and leukocytes, infiltrate the brain and migrate into the core lesion. Microglia in the surrounding areas increase in number and polarize towards a highly pro-inflammatory phenotype, expressing markers linked to oxidative stress, phagocytosis, and antigen presentation (Zrzavy et al., 2017; Figure 1, red wave). Pro-inflammatory cytokines are elevated in post-mortem tissue of stroke patients, such as interleukin (IL) 6, IL-1β, interferon (IFN) γ, tumor necrosis factor (TNF) α and IL-15 (Doll et al., 2014; Nguyen et al., 2016; Zrzavy et al., 2017; Wimmer et al., 2018). IL-1β
and TNFα levels in serum and plasma have been investigated and some studies reported an increase shortly after the stroke (Intiso et al., 2004; Sotgiu et al., 2006), whereas others did not (Tarkowski et al., 1995; Ormstad et al., 2011). However, due to the potent pro-inflammatory action of these cytokines and short half-life, a short-lived and locally restricted increase would be expected (Doll et al., 2014; Jayaraj et al., 2019). Further, many pro-inflammatory chemokines are upregulated in the brain, such as CCL1, CCL2, CCL4, CCL5, CCL22, CXCL10, and CXCL12, and some can be detected in serum or plasma (Garcia-Berrocoso et al., 2014; Nguyen et al., 2016). On the other hand, anti-inflammatory cytokines such as IL-10 are highly upregulated in early stroke lesions and initially down-regulated in the serum, but levels increase later on (Ormstad et al., 2011; Nayak et al., 2012; Nguyen et al., 2016). Peripheral IL-6 and IL-10 levels were linked to worsened or improved stroke outcomes, respectively (Jiao et al., 2016; Nguyen et al., 2016). As microglia are polarized towards a pro-inflammatory phenotype, they can produce oxygen and nitrogen (ROS and NOS) species, which lead to BBB breakdown and act as neurotoxins (Seneș et al., 2007; Jayaraj et al., 2019). Astrocytes become hyperplastic and produce chemokines, cytokines, and astrocyte-specific proteins such as vimentin, or glial fibrillary acidic protein (GFAP), which contribute to scar formation (Wang et al., 2018; Pluta et al., 2021). Astrocytes also produce ephrin-A5, extracellular matrix molecules, and chondroitin sulfate proteoglycans, which interfere with axonal sprouting, inhibit axonal growth and regeneration (Rolls et al., 2009; Overman et al., 2012; Huang et al., 2014). In the blood, increased levels of plasma lipid peroxides and thiobarbituric acids were found, a sign of ongoing oxidative stress and elevated levels of ROS and NOS (Alexandrova et al., 2003). Moreover, fraktalkine (CX3C), which can induce chemotaxis of leukocytes and microglia by binding to its receptor CX3CR1, seems to play a role in the post-ischemic outcome in an animal model, as CX3C knock-out animals had a nearly 30% reduction in infarct size and mortality (Soriano et al., 2002).

After the initial wave of inflammation, peripheral macrophages which have infiltrated the brain, together with brain-resident microglia, phagocytose debris of dead cells and shift towards either a mixed pro- and anti-inflammatory, or exclusively anti-inflammatory phenotype linked to the resolution of inflammation, removal of debris, and central nervous system (CNS) remodeling (Zrzavy et al., 2017). Pro-inflammatory mediators, such as IL-6, CXCL10, and CCL4, but also anti-inflammatory transforming growth factor (TGF) β are still significantly elevated (Nguyen et al., 2016; Jayaraj et al., 2019; Figure 1, orange wave). In post-mortem brains of patients, who died within 7 days after an ischemic insult, astrocytes were shown to produce pro-inflammatory IL-15 via activating CD8+ T cells and natural killer cells (Li et al., 2017). Lymphocytes, especially CD8+ T cells, were increased in the ischemic lesion compared to healthy controls, although the number of T cells was about 10-fold lower compared to inflammatory conditions such as multiple sclerosis or encephalitis and did not show active proliferation as a sign of antigen recognition (Zrzavy et al., 2017).

In the late cystic or scar stage, an astrocytic scar has formed around the necrotic core. In this late phase after ischemic stroke, microglia reappear within the lesion core with a partly homeostatic, partly inflammatory phenotype (Zrzavy et al., 2017). Several pro- and anti-inflammatory cytokines and chemokines are still elevated and microglia produce increased levels of various growth factors, enhancing neurogenesis and plasticity within the penumbra (Nguyen et al., 2016; Jayaraj et al., 2019; Figure 1, yellow wave). B cells have been postulated to play a role in stroke recovery in the late stage. Increased numbers of regulatory B cells were shown to be beneficial, as they secret anti-inflammatory IL-10 (Offner and Hurn, 2012). On the other hand, in a mouse model for stroke, activated B cells infiltrated the brain weeks after a stroke and secreted immunoglobulin, leading to cognitive deficits. Post-stroke cognitive decline was decreased drastically upon depletion of B cells, indicating an active role of the activated B cells in the brain (Doyle et al., 2015).

**Neuroinflammation in Epilepsy**

In epilepsy, the temporal resolution of inflammatory processes is less well established. In humans, the epileptogenic processes leading to the first seizure can occur over years during which patients are free of symptoms. Most data on human patients derive from surgical resections of drug-resistant epilepsy patients, in whom epileptogenic activity has been ongoing for years. Hence, the pathological changes characterize a very late stage of the disease, and no conclusions regarding the initial events can be drawn. Results from both, human end-point analyses and animal studies, where clear time-course studies are feasible, revealed several pro-inflammatory mediators, which are involved in epileptogenesis. The most prominent one is IL-1β, which is produced in the brain of human patients with pharmaco-resistant epilepsy and was also shown to lower the seizure threshold in animals (Vezzani et al., 1999, 2000, 2011b). IL-1β leads to an altered phosphorylation of NMDA receptors, rendering them more permeable to calcium and therefore increasing neuronal firing or potentially even excitotoxicity (Viviani et al., 2003). Moreover, patients’ serum IL-1β levels decrease after surgical resection of the epileptogenic foci (Pedre et al., 2018a). IL-6 is upregulated during epileptogenesis, decreases neurogenesis, and promotes gliosis (Minami et al., 1991; Ichiyama et al., 1998; Peltola et al., 2000; Vallières et al., 2002; Liimatainen et al., 2009; Rana and Musto, 2018). Moreover, IL-6 serum levels were reduced after surgical resection of the epileptogenic foci and were significantly reduced in epileptic patients who became seizure-free after the surgery (Pedre et al., 2018a). Further, increased levels of oxidative stress markers as a possible sign for activated, pro-inflammatory microglia, were found in the blood of epilepsy patients, which decreased after surgery (López et al., 2007; Pedre et al., 2018b). Increased levels of inducible nitric oxide synthase (iNOS) were found in post-mortem tissue of epilepsy patients (Pauletti et al., 2019; Terrone et al., 2019). TNFα can exert various pro-epileptogenic properties in the brain (Minami et al., 1991; Ichiyama et al., 1998; Arulsamy and Shaikh, 2020). It is released from activated microglia upon extracellular glutamate detection and leads to an upregulation of synapses. In vitro, TNFα induces an upregulation of AMPA receptors and the endocytosis of GABA receptors (Stellwagen et al., 2005). Chemokines have also been
directly decrease the expression of tight-junction proteins and neuronal-microglial interaction, has been shown to modulate neuronal chemokine fraktalkine (CX3CL1), which mediates with seizure frequency, making a direct link between T cells parenchyma in animals (Fabene et al., 2008, 2010; Cerri et al., 2009; Xu et al., 2009; Cerri et al., 2017). Moreover, an endothelial upregulation of chemokines can lead to increased leukocyte influx, which has been shown to act pro-convulsively and induce an epileptogenic inflammatory milieu within the brain parenchyma in animals (Fabene et al., 2008, 2010; Foresti et al., 2009; Xu et al., 2009; Cerri et al., 2017). In humans, T cell numbers were found to be uncorrelated with seizure frequency, making a direct link between T cells and epileptogenesis less likely (Tröscher et al., 2021). The neuronal chemokine fraktalkine (CX3CL1), which mediates neuronal-microglial interaction, has been shown to modulate GABA$_A$ currents in human temporal lobe epilepsy (Roseti et al., 2013; all inflammatory changes occurring in epilepsy in Figure 1 in bold).

**Astrogliosis and Glial Scar in Stroke and Epilepsy**

The astrocytic scar formed in the late stage after stroke provides a scaffold for angiogenesis, modulates immune cells and prevents the uncontrollable spread of inflammation and cell damage to healthy areas, and maintains ion and fluid balance (Rolls et al., 2009). Moreover, astrocytes forming the scar produce nerve growth factors and brain-derived neurotrophic factors (Schwartz and Nishiyama, 1994), which facilitate survival and rewiring of surviving neurons in the penumbra (Rolls et al., 2009). Several extracellular matrix proteins have also been shown to aid axonal outgrowth (Dzyubenko et al., 2018). Although neuroregeneration and rewiring are difficult in the CNS, neuronal reorganization and repair occur post-ischemia and can be enhanced by glial-derived growth factors and stimulation (Zhang and Chopp, 2009; Wahl et al., 2014, 2017).

Astrogliosis is also a hallmark of medial temporal lobe epilepsy, where areas with or without neuronal loss can be affected (Thom, 2014; Blumcke et al., 2017). Moreover, it was shown that astrocytes can change the extracellular matrix in a TGFβ-dependent manner, leading to a breakdown of perineuronal nets around inhibitory neurons, triggering inhibition deficits (Kim et al., 2017). Disruption of the extracellular matrix leads to altered ion concentrations, osmolarity, and firing behavior in hippocampal neurons (Glykys et al., 2014). Astrocytes also play a critical role with respect to ion balancing, especially potassium buffering, and neurotransmitter homeostasis. These mechanisms have been shown to be altered in epilepsy surgical resections (Pekny et al., 2016).

**Blood-Brain-Barrier Breakdown in Stroke and Epilepsy**

Another hallmark of stroke is BBB breakdown. This is mainly mediated by proteases such as metalloproteases (mainly MMP2 and MMP9), which are induced by hypoxia-inducible factor (HIF) 1α or various pro-inflammatory cytokines. They directly decrease the expression of tight-junction proteins and shift their location. MMP9 levels were found to be increased after ischemic stroke and positively correlate with the severity of neurological deficits. Interestingly, MMP9 levels dropped after 72 h, except in patients with stroke progression (Brouns et al., 2011). Integrins, which under physiological conditions interact with the basement membrane to control BBB permeability, also break down, leading to edema and exacerbated inflammation (Yang and Rosenberg, 2011). In rodent stroke models, reactive oxygen species were shown to further enhance BBB leakage (Kim et al., 2001). Breakdown of the BBB leads to leakage of peripheral proteins such as albumin, which by itself acts highly pro-inflammatory within the brain parenchyma (Brouns et al., 2011; Altman et al., 2019; Yang et al., 2019).

**BBB leakage also commonly occurs in epilepsy and also increases the risk of developing epilepsy after a precipitating incident** (Marchi et al., 2007, 2010, 2012; van Vliet et al., 2007; Tomkins et al., 2008; Raabe et al., 2012). Peripheral proteins can induce seizures and lead to imbalances in brain homeostasis and trigger inflammation. Albumin was shown to decrease potassium buffering in a TGFβ-dependent manner (Schröder et al., 2000; Jauch et al., 2002; Cacheaux et al., 2009; Frigerio et al., 2012; Heinemann et al., 2012; Devinsky et al., 2013; Gorter et al., 2019). Moreover, seizures themselves can lead to increased BBB permeability (Marchi et al., 2007, 2012; van Vliet et al., 2007; Tomkins et al., 2008; Morin-Brureau et al., 2011; Devinsky et al., 2013; Vezzani et al., 2019). The importance of BBB leakage with respect to the development of PSE is further underlined by the fact that statins reduce the risk for hospitalization for epilepsy after stroke in a dose-dependent manner. Their effect is mainly ascribed to their anti-inflammatory and protective action on the BBB (Xu et al., 2020; Fang et al., 2021; Guo et al., 2021).

**Alarmins in Stroke and Epilepsy**

Inflammation in stroke as well as in epilepsy can be initiated, propagated, and maintained by the release of alarmins, which are mostly intracellular molecules released upon cellular stress or death. In stroke, various alarmins, such as the protein high-mobility group box 1 (HMGB1), purins, or peroxireduoxins, are released and bind to various damage associated molecular pattern receptors (DAMPs), initiating an inflammatory cascade (Gülke et al., 2018). HMGB1 activates the receptor for advanced glycation products (RAGE) as well as toll-like receptor (TLR) 2 and 4, which are also activated by peroxireduoxins. Similar pathways, mediated via HMGB1, RAGE, and TLR4 were shown to be upregulated in epilepsy animal models and surgical resections of epilepsy patients (Zurolo et al., 2011; Paudel et al., 2019). HMGB1 was also found in the serum of stroke patients and high levels were linked to a worse outcome, indicated by higher follow-up modified Rankin scores at 1 year (Tsukagawa et al., 2017). Binding to these receptors initiates NFκB signaling, which induces the transcription of several highly pro-inflammatory chemokines and cytokines (Liu et al., 2017) and was shown to be activated in hippocampal resections of medial temporal lobe epilepsy patients (Crespel et al., 2002). Purins, which are released from dying cells after seizures or ischemia, can activate the inflammasome via Nod-like receptor (NLRP) 3, which triggers the secretion of...
IL1β and IL18 (Beamer et al., 2016; Gülke et al., 2018). The inflammasome or its products IL1β and IL18 have been shown to be upregulated in various epilepsies (Tröscher et al., 2019; Vezzani et al., 2019).

**Commonalities in the Inflammatory Activation Between Epilepsy and Stroke**

There is a significant overlap of inflammatory mechanisms after an ischemic infarct compared to findings in epilepsy patients. Pro-inflammatory cytokines, such as IL-6, IL-1β, and TNFα have been described in brains and in the blood of both, patients after stroke and in epilepsy (Table 1; Stellwagen et al., 2005; Doll et al., 2014; Nguyen et al., 2016; Zrzavy et al., 2017; Pedre et al., 2018a; Rana and Musto, 2018; Wimmer et al., 2018; Vezzani et al., 2019). Especially the pro-epileptogenic action of IL-1β and TNFα are well understood and their upregulation after ischemia could be a possible explanation for post-ischemic epileptogenesis (Stellwagen et al., 2005; Vezzani et al., 2019). Alarmins, secreted due to neuronal damage or cell death caused by the ischemia, may augment the inflammatory reaction and activate pro-epileptogenic pathways via pro-inflammatory cytokines (Vezzani et al., 2011b; Gülke et al., 2018). A recent study found downregulation of calcium-binding protein B (S100B) and heat-shock protein (Hsc70) as well as an upregulation of endostatin in patients directly after stroke, who had a high probability of developing PSE in the following months (Abraira et al., 2020). S100B and Hsc70 are DAMPs linked to BBB integrity, hence lower levels could point towards perturbed BBB function (Galovic et al., 2021).

In addition, T cell and monocyte-attracting chemokines are expressed in the early, intermediate, and late stages after an ischemic infarct and in epilepsy resections (Fabene et al., 2010; García-Berrocoso et al., 2014; Cerri et al., 2017). How these chemokines act pro-epileptogenically is not yet fully understood, but T cells have been shown to infiltrate the brain in both epilepsy and after an ischemic stroke, albeit in low numbers (Zrzavy et al., 2017; Tröscher et al., 2021). However, a recent study showed that the number of T cells in medial temporal lobe epilepsy does not correlate with the seizure frequency. Therefore, parenchymal T cells are unlikely to be the key driver of post-ischemic epileptogenesis (Tröscher et al., 2021). However, so far little is known about the parenchymal inflammatory milieu in PSE brains.

Gliaal scar forming astrocytes are present around the lesion core after an ischemic infarct and are commonly found in epilepsy patients, for example in hippocampal sclerosis (Rolls et al., 2009; Robel and Sontheimer, 2015; Wang et al., 2018). Moreover, astrocytes play a key role in neurotransmitter homeostasis (Pekny et al., 2016). The glial scar and excessively produced extracellular matrix proteins around the lesion core may inhibit axonal regrowth and prevent physiological synaptic sprouting. Therefore, excessive scar formation around the lesion could potentially affect surviving neurons within the penumbra / scar area or neurons in the neighboring areas (Glykys et al., 2014; Robel and Sontheimer, 2015; Pekny et al., 2016; Wang et al., 2018). On the other hand, astrogial scars were also shown to produce neuronal growth factors and act beneficially in post-stroke rewiring (Schwartz and Nishiyama, 1994; Do Carmo Cunha et al., 2007; Rolls et al., 2009; Zhang and Chopp, 2009).

In brain specimens of epilepsy patients, synaptic sprouting was also observed, where it was ascribed to inducing or facilitating seizure generation (Proper et al., 2000; Jarero-Basulto et al., 2018). Disturbances of previously functional networks have been shown by EEG recordings, where prolonged disturbed gamma oscillations were found in animal models and also correlated with stroke recovery in humans (Vecchio et al., 2019; Hazine et al., 2021).

Astrocytes play another critical role in post-ischemic parenchymal processes via their endfeet, constituting a part of the BBB (Alvarez et al., 2013). After ischemic infarcts, the BBB often breaks down leading to the influx of peripheral molecules and cells (Brouns et al., 2011). In epilepsy, BBB leakage is a commonly observed phenomenon and was repeatedly described as triggering or enhancing epileptic activity (Friedman, 2011). Therefore, chronic alterations in the BBB could be another mechanism by which PSE develops and how epileptic activity persists even months and years after the ischemic lesion occurred.

**DISCUSSION AND FUTURE DIRECTIONS**

Although PSE is one of the most common forms of acquired epilepsy in the elderly, surprisingly little is known about the underlying pathomechanisms. One of the most common theories for post-ischemic epileptogenesis is chronic inflammation, which can occur in stroke patients but also in patients suffering from epilepsy. Many studies have investigated the inflammatory cascades occurring after stroke (for review see Wimmer et al., 2018; Jayaraj et al., 2019). In epilepsy research chronic inflammation has been delineated as a potent driver of epileptogenesis as well (Wilcox and Vezzani, 2014; Bauer et al., 2017; Vezzani et al., 2019). However, hardly anything is known about the interaction of these two pathomechanisms.

In recent years, crucial scientific work has been done to pave the way for future studies, among them establishing a sensitive clinical screening tool for patients at high risk of developing PSE (Galovic et al., 2018). This will allow for designing studies to investigate possible pathomechanisms and therapeutic approaches for PSE by pre-selecting susceptible patients. Previously, designing prospective studies on PSE was hardly realistic due to the relatively low percentage of patients developing PSE. Using the SELECT score, a patient pool with patients at high risk for PSE can be generated and followed up. First investigations on blood biomarkers in PSE have recently been published and underline the fact, that inflammatory processes might be involved in the pathomechanism of PSE (Abraira et al., 2020). Furthermore, the recently published meta-analyses on the beneficial effect of statins on the development of PSE point towards a pro-inflammatory origin of RSS (Guo et al., 2015; Xu et al., 2020; Fang et al., 2021). As clinical research on PSE is very laborious and time-consuming, translational research would be very useful to understand the basic pathomechanisms. However, generating animal models is equally difficult, as mice and rats...
also tend to develop seizures after stroke in relatively low numbers. Hence, high numbers of animals would be required for reliable and reproducible results. Moreover, the validity of results gained from young rodents for a human disease affecting the elderly is questionable (Reddy et al., 2017). In vitro approaches using human iPSCs or organotypic slices could lead to insights on basic molecular principles of post-ischemic epileptogenesis with human cells or tissues. However, most likely only combining results from all three approaches will lead to a better understanding of the underlying pathomechanism of post-ischemic PSE and thus help to identify targets for therapy and prophylaxis.

We summarized the key inflammatory mediators involved in both diseases and provided a broad overview on potential post-ischemic epileptogenic mechanisms. In the future, these questions have to be addressed in clinical as well as translational research to provide insights into the development of PSE. In animal models, the basic principles of post-ischemic inflammation and their potential to drive epileptogenesis can be studied in detail, allowing exactly timed disease course analyses and in vivo monitoring of neuronal activity. Moreover, in animal models confounding factors such as lesion size, age, and area of incident can easily be controlled for. In clinical research, the quest for biomarkers in easily accessible compartments, such as the blood, will be crucial. Moreover, electroencephalographic and imaging approaches can be used in human clinical research to identify key epileptogenic hubs and their specific firing properties during the latent phase of epileptogenesis. This will not only improve our basic understanding of post-ischemic brain physiology but also pave the way for potential prophylactic interventions, inhibiting epileptogenesis before the first seizure occurs.

**AUTHOR CONTRIBUTIONS**

AT and VB summarized the molecular biological aspects of stroke and epilepsy. JG and JW summarized the clinical aspects of PSE. A-SW contributed with her knowledge on stroke and stroke rehabilitation. AT wrote the manuscript. TO supervised the project. All authors contributed to the article and approved the submitted version.

**FUNDING**

AT was supported by the Austrian Epilepsy Association. A-SW was supported by the Dr. Hurka Foundation, Zurich. This work was supported by Johannes Kepler Open Access Publishing Fund.

**REFERENCES**

Abraira, L., Santamarina, E., Cazorla, S., Bustamante, A., Quintana, M., Toledo, M., et al. (2020). Blood biomarkers predictive of epilepsy after an acute stroke event. *Epilepsia* 61, 2244–2253. doi: 10.1111/epi.16648

Alexandrova, M. L., Bochev, P. G., Markova, V. I., Bechev, B. G., Popova, M. A., Danovska, M. P., et al. (2003). Oxidative stress in the chronic phase after stroke. *Redox Rep.* 8, 169–176. doi: 10.1199/redx.2003.0225001548

Altman, K., Shavit-Stein, E., and Maggio, N. (2019). Post stroke seizures and epilepsy: from proteases to maladaptive plasticity. *Front. Cell. Neurosci.* 13:397. doi: 10.3389/fncel.2019.00397

Alvarez, J. I., Katayama, T., and Prat, A. (2013). Glial influence on the blood brain barrier. *Glia* 61, 1939–1958. doi: 10.1002/glia.22575

Arusamy, A., and Shaikh, M. F. (2020). Tumor necrosis factor-α mediated post-stroke neuronal apoptosis via the TNF-α receptor-1 pathway. *ACS Chem. Neurosci.* 11, 1900–1908. doi: 10.1021/acschemneuro.0c00301

Baranowski, C. J. (2018). The quality of life of older adults with epilepsy: a systematic review. *Seizure* 60, 190–197. doi: 10.1016/j.seizure.2018.06.002

Bauer, J., Becker, A. J., Elyaman, W., Peltola, J., Ruegg, S., Titulaer, M. J., et al. (2017). Innate and adaptive immunity in human epilepsies. *Epilepsia* 58, 57–68. doi: 10.1111/epi.13784

Beamer, E., Gölnöösær, F., Horváth, G., Beko, K., Otrokovics, L., Koványi, R., et al. (2016). Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. *Neuropsychopharmacology* 40, 94–104. doi: 10.1016/j.neuropharm.2015.09.019

Bentcs, C., Martins, H., Peralta, A. R., Cassimiro, C., Morgado, C., Franco, A. C., et al. (2017). Post-stroke seizures are clinically underestimated. *J. Neurol.* 264, 1978–1985. doi: 10.1007/s00415-017-8586-9

Blumcke, I., Sprefico, R., Haaker, G., Coras, R., Kobow, K., Bien, C. G., et al. (2017). Histopathological findings in brain tissue obtained during epilepsy surgery. *N. Engl. J. Med.* 377, 1648–1656. doi: 10.1056/NEJMoa1703784

Brouns, R., Wauters, A., De Surgeloose, D., Marien, P., and De Deyn, P. P. (2011). Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. *Eur. Neurol.* 65, 23–31. doi: 10.1159/000321965

Cacheaux, L. P., Ivens, S., David, Y., Lakhter, A. J., Bar-Klein, G., Shapira, M., et al. (2009). Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. *J. Neurosci.* 29, 8927–8935. doi: 10.1523/JNEUROSCI.0430-09.2009

Caplan, L. R. and Kase, C. S. (2016). “Intracerebral hemorrhage,” in *Caplan’s Stroke: A Clinical Approach*, ed L. R. Caplan (Cambridge University Press), 477–510. doi: 10.1017/CBO978110695805.015

Cerri, C., Caleo, M., and Bozzi, Y. (2017). Chemokines as new inflammatory players in the pathogenesis of epilepsy. *Epilepsia Res.* 136, 77–83. doi: 10.1016/j.ejare.2017.07.016

Crespel, A., Coubes, P., Rousset. M.-C., Brana, C., Rougier, A., Rondouin, G., et al. (2002). Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. *Brain Res.* 952, 159–169. doi: 10.1016/S0006-8993(02)03050-0

Deuschl, G., Beghi, E., Fazekas, F., Varga, T., Christoforidis, K. A., Sipido, E., et al. (2020). The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. *Lancet Public Health* 5, e551–e567. doi: 10.1016/S2468-2667(20)30190-0

Devinsky, O., Vezzani, A., Najjar, S., De Lanerolle, N. C., and Rogawski, M. A. (2013). Glia and epilepsy: excitability and inflammation. *Trends Neurosci.* 36, 174–184. doi: 10.1016/j.tins.2012.11.008

Do Carmo Cunha, J., De Freitas Azevedo Levy, B., De Luca, B. A., De Andrade, M. S. R., Comide, V. C., and Chadi, G. (2007). Responses of reactive astrocytes containing S100 protein and fibroblast growth factor-2 in the border and in the adjacent preserved tissue after a contusion injury of the spinal cord in rats: implications for wound repair and neuroregeneration. *Wound Repair Regen.* 15, 134–146. doi: 10.1111/j.1524-475X.2006.00194.x

Doll, D. N., Barr, T. L., and Simpkins, J. W. (2014). Cytokines: their role in stroke and stroke rehabilitation. *Acta Neuropathol.* 128, 29–36. doi: 10.1007/s00401-014-1428-8

Dwyer, J. A., McCall, J. L., Parkinson, J., and McQuade, J. (2004). Ischemic stroke correlate with evolution and outcome. *Eur. Neurol.* 65, 23–85. doi: 10.1159/000321965

Erb, M., Evers, C., Zang, K., and Schliewen, U. K. (2006). GDF-15, a novel biomarker for acute ischemic stroke. *Eur. Neurol.* 56, 18–25. doi: 10.1159/000084024

Etienne, H., Hauser, S., et al. (2009). Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. *J. Neurosci.* 29, 8927–8935. doi: 10.1523/JNEUROSCI.0430-09.2009
Tröscher et al. Inflammation and Post-stroke Epileptogenesis

Fabene, P. F., Bramanti, P., and Constantin, G. (2010). The emerging role for chemokines in epilepsy. J. Neuroimmunol. 224, 22–27. doi: 10.1016/j.neuroim.2010.05.016

Fabene, P. F., Navarro Mora, G., Martinello, M., Rossi, B., Mergo, F., Ottoboni, L., et al. (2008). A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med. 14, 1377–1383. doi: 10.1038/nm.1878

Fang, J., Tuo, M., Ouyang, K., and Xu, Y. (2021). Statin treatment reduces the risk of poststroke seizures. J. Neuroinflammation 18, 1–3. doi: 10.1186/s12974-021-02404-x

Ferreira-Atuesta, C., Döhler, N., Erdélyi-Canavese, B., Felbecker, A., Siebel, P., Conrad, J., et al. (2021). Seizures after ischemic stroke: a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurol. 17, 143–152. doi: 10.1016/S1474-4422(21)00040-4

Galovic, M., Ferreira-Atuesta, C., Abraira, L., Döhler, N., Sinka, L., Brigo, F., et al. (2021). Seizures and epilepsy after stroke: epidemiology, biomarkers and management. Drugs Aging 38, 285–299. doi: 10.1007/s40266-021-00837-7

García-Berrocoso, T., Giralt, D., Llombart, V., Bustamante, A., Penalba, A., García-Manteca, F., et al. (2014). Chemokines after human ischemic stroke: from microglia activation to blood-brain barrier disruption and oxidative cellular injury after photothrombotic cortical ischemia in mice. Stroke 45, 1007–1018. doi: 10.1161/strokeaha.111.000220

Gülke, J., Dzhala, V., Egawa, K., Balena, T., Sapojnjic, Y., Kuchihiotla, K. V., et al. (2014). Local imparment anions establish the neuronal chloride concentration. Science 343, 670–675. doi: 10.1126/science.1245423

Gorter, J. A., Aronica, E., and van Vliet, E. A. (2019). The roof is leaking and a storm is raging: repairing the blood-brain barrier in the fight against epilepsy. Therapeutics (Basel) 11:17. doi: 10.3390/ph11010017

Jauch, R., Windmüller, O., Lehmann, T. N., Heinemann, U., and Gabriel, S. (2002). Effects of barium, furosemide, ouabaine and 4,4'-disothiocyanostilbene-2,2'-disulphonic acid (DIDS) on ionophoretically-induced changes in extracellular potassium concentration in hippocampal slices from rats and from patients with epilepsy. Brain Res. 925, 18–27. doi: 10.1016/s0006-8993(01)03254-1

Jayaraj, R. R., Azimuthall, S., Beiram, R., Jalal, F. Y., and Rosenberg, G. A. (2019). Neuroinflammation: friend and foe for ischemic stroke. J. Neuroinflammation 16:142. doi: 10.1186/s12974-019-1516-2

Jiao, J.-T., Cheng, C., Ma, Y.-J., Huang, J., Dai, M.-C., Jiang, C., et al. (2016). Association between inflammatory cytokines and the risk of post-stroke depression and the effect of depression on outcomes of patients with stroke in a 2-year prospective study. Exp. Ther. Med. 12, 1591–1598. doi: 10.3892/etm.2016.3494

Kim, G. W., Lewin, A., Copin, J. C., Watson, B. D., and Chan, P. H. (2001). The cytosolic antioxidant, copper/zinc superoxide dismutase, attenuates blood-brain barrier disruption and oxidative cellular injury after photothrombotic cortical ischemia in mice. Neuroscience 105, 1007–1018. doi: 10.1016/s0306-4522(01)00627-8

Kim, S. Y., Senatorov, V. V., Morrisey, C. S., Lippmann, K., Vazquez, O., Milikovsky, D. Z., et al. (2017). TGFβ signaling is associated with changes in inflammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults. Sci. Rep. 7:7711. doi: 10.1038/s41598-017-07394-3

Lekoubou, A., Debroy, K., Kweyir-Aggrey, A., Bonilha, L., Kengne, A., and Chinchilli, V. (2021). Risk models to predict late-onset seizures after stroke: a systematic review. Epilepsy Behav. 121:108003. doi: 10.1016/j.yebeh.2021.108003

Li, M., Li, Z., Yao, Y., Jin, W. N., Wood, K., Liu, Q., et al. (2017). Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc. Natl. Acad. Sci. U S A 114, E396–E405. doi: 10.1073/pnas.1621930114

Li, S., Overman, J. J., Katsman, D., Kozlov, S. V., Donnelly, C. J., Twiss, J. L., et al. (2010). An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. Nat. Neurosci. 13, 1496–1504. doi: 10.1038/nn.2674

Limumtaine, S., Fallah, M., Kharazmi, E., Peltola, M., and Peltola, J. (2009). Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy. J. Neurosci. 256, 796–802. doi: 10.1007/s00415-009-2021-x

Liu, T., Zhang, L., Joo, D., and Sun, S. C. (2017). NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2:17023. doi: 10.1038/sigtrans.2017.23
Tröscher et al. Inflammation and Post-stroke Epileptogenesis

Frontiers in Aging Neuroscience | www.frontiersin.org 10 December 2021 | Volume 13 | Article 781174

Williams, A. J., and Tortella, F. C. (2002). Neuroprotective effects of the sodium channel blocker RS108642 and attenuation of ischemia-induced brain seizures in the rat. Brain Res. 932, 45–55. doi: 10.1016/s0006-8993(02)02775-8

Wimmer, I., Zrzavy, T., and Lassmann, H. (2018). Neuroinflammatory responses in experimental and human stroke lesions. J. Neuroimmunol. 323, 10–18. doi: 10.1016/j.jneuroim.2018.07.003

Wu, Y., Wang, X., Mo, X., Xi, Z., Xiao, F., Li, J., et al. (2008). Expression of monocyte chemoattractant protein-1 in brain tissue of patients with intractable epilepsy. Clin. Neuropathol. 27, 55–63. doi: 10.5414/npb27055

Xu, M. Y. (2019). Poststroke seizure: optimising its management. Stroke. 48, 44–56. doi: 10.1161/SYSV-2018-001175

Xu, J. H., Long, L., Tang, Y. C., Zhang, J. T., Hu, H. T., and Tang, F. R. (2009). CCR3, CCR2A and macrophage inflammatory protein (MIP)-1α, monocyte chemotactic protein-1 (MCP-1) in the mouse hippocampus during and after pilocarpine-induced status epilepticus (PISE). Neuropathol. Appl. Neurobiol. 35, 496–514. doi: 10.1111/j.1365-2990.2009.01022.x

Xu, T., Wang, Y., Yuan, J., Chen, Y., and Luo, H. (2020). Statin use and the risk of post-stroke seizures—a meta-analysis. Seizure 83, 63–69. doi: 10.1016/j.seizure.2020.10.004

Yang, C., Hawkins, K. E., Doré, S., and Candelario-Jalil, E. (2019). Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am. J. Physiol. Cell Physiol. 316, C135–C153. doi: 10.1152/ajpcell.00136.2018

Yang, Y., and Rosenberg, G. A. (2011). Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 42, 3323–3328. doi: 10.1161/STROKEAHA.110.680257

Zelano, I., Holkamp, M., Agarwal, N., Lattanzi, S., Trinka, E., and Brigo, F. (2020). How to diagnose and treat post-stroke seizures and epilepsy. Epileptic Disord. 22, 252–263. doi: 10.1523/EPD.2020.1159

Zhang, Z. G., and Chopp, M. (2009). Neurorestoratve therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 8, 491–500. doi: 10.1016/S1474-4422(09)70061-4

Zrzavy, T., Machado-Santos, J., Christine, S., Baumgartner, C., Weiner, H. L., Butovsky, O., et al. (2017). Dominant role of microglial and macrophage innate immune responses in human ischemic infarcts. Brain Pathol. 28, 791–805. doi: 10.1111/bpa.12583

Zurolo, E., Iyer, A., Maroso, M., Carbonell, C., Anink, J. J., Ravizza, T., et al. (2011). Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 134, 1015–1032. doi: 10.1093/brain/awr032

Conflict of Interest: JW reports personal fees from UCB and Boehringer Ingelheim and non-financial support from Roche, outside the submitted work; TO reports personal fees and non-financial support from Eisai Pharma GmbH Vienna, grants, personal fees, and non-financial support from UCB Pharma GmbH Vienna, non-financial support from Medtronic Austria GmbH, grants, personal fees, and non-financial support from Novartis Pharma, personal fees from Roche Pharma, personal fees from Biogen Idec Austria, personal fees from Liva Nova, personal fees from Sanofi-Aventis GmbH, grants from Grossegger & Drbal GmbH, outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Tröscher, Gruber, Wagner, Böhm, Wahl and von Oertzen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.